ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Investors applaud Fosun role in promising Pfizer COVID vaccine

Unit of Chinese conglomerate has partnered with Germany's BioNTech

SHANGHAI -- Shares in the main pharmaceuticals unit of Chinese conglomerate Fosun International rose sharply on Tuesday as investors applauded its role in what could be a breakthrough global COVID-19 vaccine.

Pfizer, the U.S. pharma group, and Germany's BioNTech said on Monday that their candidate mRNA vaccine BNT162b2 had demonstrated efficacy of over 90% based on an analysis of its pre-manufacturing phase 3 clinical trial, usually the last hurdle before a drug goes into production.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more